Disease Severity at Month 30 in ATTR-ACT: Tafamidis Meglumine 80 mg Versus Placebo-treated Patients10
At Month 30 in ATTR-ACT (prior to enrolling in the LTE), patients who had received placebo had more severe disease versus patients treated with tafamidis meglumine 80 mg, as assessed by:
6MWT |
Walk distance:* 333.8 meters (± 117.5) in the placebo group versus 364.7 meters (± 126.1) in the tafamidis meglumine 80 mg group |
KCCQ-OS |
Score:* 53.4 (± 24.4) in the placebo group versus 69.1 (± 21.2) in the tafamidis meglumine 80 mg group |
NT-proBNP† |
Tafamidis meglumine (80 mg)
2620.5 (1492.1-4405.0)
Placebo
Tafamidis meglumine (80 mg)
Placebo
4775.6 (3631.0-6911.0)
0
1000
2000
3000
4000
5000
|
*Data are mean (± standard deviation).
†Data are median (interquartile range).
6MWT: 6-minute walk test; ATTR-ACT: Tafamidis in Transthyretin Cardiomyopathy Clinical Trial; KCCQ-OS: Kansas City Cardiomyopathy Questionnaire Overall Summary Score; LTE: long-term extension; NT-proBNP: N-terminal pro-B type natriuretic peptide.
